A diagnostic technology from NanoSomiX may be useful in measuring prognosis and treatment of Alzheimer’s disease.
Singapore-based Vela Diagnostics has announced completion of the FDA listing of its next-generation sequencing system as a Class II medical device.
Updated ACS guidelines for colorectal cancer include recommended use of a noninvasive stool-based DNA screening test every 3 years.
A new partnership between BBI Solutions and Genisphere will focus on developing lateral-flow rapid test applications with heightened levels of sensitivity.
Presentations at ACR are expected to offer new data about the diagnostic and clinical utility of blood tests for the protein 14-3-3 eta, considered a mechanistic biomarker for rheumatoid arthritis.
A CDC study suggests there is room for improvement in current approaches for screening and prevention of cervical cancer.
US testing for chikungunya is unlikely to taper off during the fall and winter, as travelers returning from outbreak areas remain at risk.
The combination of LabCorp and Covance will create a comprehensive healthcare diagnostics company offering customers end-to-end solutions for drug and diagnostics development and commercialization.
In a recent study, the ISET test by Rarecells detected lung cancer in patients with no symptoms, allowing for surgical removal prior to metastasis.
Selling its US health services unit will enable Alere to sharpen its focus on enhancing leadership in the global rapid diagnostics market.